First Potential FDA-Approved Therapy for wAIHA

Summary Johnson & Johnson presented pivotal ENERGY Phase 2/3 data showing statistically significant durable hemoglobin responses for IMAAVY in warm autoimmune hemolytic anemia, supporting its February 2026 sBLA filing. What Happened Patients receiving IMAAVY achieved durable hemoglobin responses at roughly three times the rate of…